Opportunity to undertake an MSc in Health Economics at the University of London

By HEOR Staff Writer

February 10, 2023

Health Economics Fellowship Programme

Opportunity to undertake an MSc in Health Economics at the University of London. Apply for a Fellowship Programme by 30 April 2023.

The Office of Health Economics (OHE) provides various forms of support to the upcoming generation of health economists in order to fulfil our philanthropic goals. They have established an MSc Fellowship Programme in collaboration with City, University of London, and a PhD Programme at LSE, London School of Economics and Political Science, for individuals interested in pursuing postgraduate studies in health economics.

Their objective is to ensure the continued role of health economics in high-quality, evidence-based health policy decision-making and to strengthen and advance the discipline’s future.

For further information, please visit:

Reference url

Recent Posts

Tovorafenib clinical assessment
Tovorafenib Clinical Assessment Outcomes and Methodological Challenges

By João L. Carapinha

June 9, 2026

The Tovorafenib clinical assessment conducted under the EU Joint Clinical Assessment process has exposed critical shortcomings in the evidence base for treating BRAF-altered pediatric low-grade glioma. Despite the therapy’s potential, reviewers concluded that robust comparative data is absent for...
MDD treatment modeling
Pioneering MDD Treatment Modeling for Optimal Care Pathways

By João L. Carapinha

June 8, 2026

MDD treatment modeling demonstrates that sequenced interventions for major depressive disorder consistently deliver superior quality-adjusted life years and net monetary benefits compared with no active treatment. All examined pathways outperformed inaction, with an SSRI-first sequence followed b...
Levacetylleucine A-T treatment
Transformative Impact of Levacetylleucine A-T Treatment in Rare Neurodegenerative Disease

By HEOR Staff Writer

June 8, 2026

Levacetylleucine A-T treatment has delivered compelling Phase III results, producing statistically significant and clinically meaningful improvements in ataxia severity and daily function for both pediatric and adult patients with ataxia-telangiectasia (A-T). The